✦ LIBER ✦

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

✍ Scribed by Sanon, Myrlene; Taylor, Douglas C.A.; Parthan, Anju; Coombs, John; Paolantonio, Marc; Sasane, Medha

Book ID: 127200951
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 624 KB
Volume: 16
Category: Article
ISSN: 1369-6998
DOI: 10.3111/13696998.2012.709204

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN27 Clinical Benefit and Economic Impa

PCN27 Clinical Benefit and Economic Impact of Three-Years of Adjuvant Imatinib in KIT+ Gastrointestinal Stromal Tumors (GIST)

✍ Sanon, M.; Parthan, A.; Taylor, D.C.; Coombs, J.; Paolantonio, M.; Sasane, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN99 COST-EFFECTIVENESS OF IMATINIB AS

PCN99 COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE

✍ Ouagari K El; V Pawar; J Coombs; J Rubin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Anti-CTLA-4 enhances the effect of imati

Anti-CTLA-4 enhances the effect of imatinib in gastrointestinal stromal tumor (GIST)

✍ Teresa S. Kim; Michael J. Cavnar; Eric C. Sorenson; Shan Zeng; Jonathan B. Greer 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Impact of Surgery on Advanced Gastrointe

Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era

✍ S. Bonvalot; H. Eldweny; C. Le Péchoux; D. Vanel; P. Terrier; A. Cavalcanti; C. 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 295 KB

Cost Effectiveness of Imatinib Mesylate

Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

✍ Dr Daniel M. Huse, Margaret von Mehren, Gregory Lenhart, Heikki Joensuu, Charles 📂 Article 📅 2007 🏛 Springer International Publishing AG 🌐 English ⚖ 118 KB

Adjuvant and neoadjuvant imatinib therap

Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

✍ Burton L. Eisenberg; Jonathan C. Trent 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 212 KB

## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off